Commonly used preventive therapy for recurrent miscarriage proved ineffective in large trial

July 3, 2018, European Society of Human Reproduction and Embryology

An immune response to pregnancy (in which the uterus rejects the embryo or foetus) is said to explain a large number of otherwise "unexplained" miscarriages. Thus, preventive treatment designed to suppress this immunological rejection during implantation and pregnancy has become a commonly accepted—albeit innovative—approach to preventing recurrent pregnancy loss. A range of "immunomodulatory" treatments are offered, most of which are non-evidence based and the latest of which is a drug known as recombinant human granulocyte-colony stimulating factor (rhG-CSF), a regulator of neutrophils and other lymphocytes activating and protecting the immune system. This is widely used (and licensed) in cancer medicine to increase white blood cells after chemotherapy.

Now, a large randomised placebo-controlled study—the largest of its kind, the RESPONSE trial—described here today at the 34th Annual Meeting of ESHRE has found no evidence that rhG-CSF given in the first trimester of improves outcomes in women with a history of unexplained recurrent pregnancy losses. The results are presented by honorary research fellow Dr. Abey Eapen from Tommy's National Centre for Miscarriage Research at the University of Birmingham, UK, and the University of Iowa Hospital and Clinics, USA. The study, a controlled randomised trial involving 150 women with a history of unexplained miscarriage, was performed at 21 hospitals in the UK.

As background to the study Eapen said that evidence in favour of rhG-CSF in the prevention of recurrent pregnancy loss was based on just one single-centre randomised trial and four further observational studies, which all suggested a statistically significant increase in pregnancy and live birth rates in the groups.

In this study, with an endpoint defined as clinical pregnancy rate at 20 weeks gestation, 76 women were randomised to rhG-CSF and 74 to placebo. All subjects had had at least three unexplained miscarriages, were aged between 18 and 37 years, and were trying to conceive naturally.

At follow-up, results showed a clinical pregnancy rate at 20 weeks of 59.2% in the rhG-CSF group, and of 64.9% in the placebo group, suggesting a neutral effect of the treatment. With further follow-up, these rates were similarly evident in live birth.

"Worldwide, granulocyte-colony stimulating factor is widely used in reproductive medicine to treat pregnancies conceived both naturally and after assisted reproduction following recurrent miscarriages," said Eapen. "Some studies have suggested statistically significant improvements in clinical pregnancy rates, but we here have high quality evidence that rhG-CSF is not an effective treatment for patients with unexplained recurrent miscarriages."

Miscarriage—whether recurrent or not—is a common and distressing complication of pregnancy, especially in IVF when so much emotion and effort has been invested in treatment. Estimates are that around 1-2% of all couples experience , but Eapen said that it is difficult of estimate the actual numbers using rhG-CSF. "It's a relatively new treatment and is offered mainly through private miscarriage and IVF clinics."

He also described reproductive immunology is a "relatively new and young" branch of reproductive medicine. "We first need to agree on an acceptable definition based on reliable and reproducible laboratory investigations before labelling a miscarriages as immune mediated," he said. "Most of immunotherapy medications tested so far through high quality trials have been shown to offer no benefit. Women diagnosed with recurrent are vulnerable, so it's important that, if they're given immune modulatory treatment for , they are counselled about success rates and potential risk/benefits, even in a research setting, let alone routine clinical practice."

Even after a diagnosis of recurrent miscarriage, the majority of pregnancies do have a favorable outcome. "But," said Eapen, "it is still very important that these women are investigated and managed in a specialist miscarriage clinic for counselling, support, evidence-based investigation, and an opportunity to take part in research. Healthy diet and management of modifiable risk factors may also help."

Explore further: Progesterone supplements do not improve outcomes for recurrent miscarriages

More information: Abstract O-064, Tuesday 3 July 2018 - Recombinant Human Granulocyte - Colony Stimulating Factor (rhG-CSF) in women with unexplained recurrent pregnancy losses (RESPONSE Study): randomised, double-blind, multicentre, placebo controlled trial

Related Stories

Progesterone supplements do not improve outcomes for recurrent miscarriages

November 25, 2015
New research from the University of Birmingham has shown that progesterone supplements in the first trimester of pregnancy do not improve outcomes in women with a history of unexplained recurrent miscarriages.

Removal of fibroids that distort the womb cavity may prevent recurrent miscarriages

September 28, 2011
Researchers have found the first, firm evidence that fibroids are associated with recurrent miscarriages. They have also discovered that if they removed the fibroids that distorted the inside of the womb, the risk of miscarriage ...

A commonly offered add-on treatment for IVF fails to provide any benefit in a large randomized trial

July 3, 2018
An add-on treatment commonly offered to female IVF patients to improve their chance of success has been shown in a large randomised trial to be of no value. "Endometrial scratch", a technique whereby a small scratch or tissue ...

Insufficient vitamin D linked to miscarriage among women with prior pregnancy loss

May 30, 2018
Among women planning to conceive after a pregnancy loss, those who had sufficient levels of vitamin D were more likely to become pregnant and have a live birth, compared to women with insufficient levels of the vitamin, according ...

Pre-pregnancy progesterone helps women with recurrent pregnancy loss

January 9, 2017
Women who have had two or more unexplained miscarriages can benefit from natural progesterone treatment before pregnancy, a new a study shows.

Lack of stem cells to blame for recurrent miscarriages

March 7, 2016
Scientists at the University of Warwick have discovered that a lack of stem cells in the womb lining is causing thousands of women to suffer from recurrent miscarriages.

Recommended for you

Human Cell Atlas study reveals maternal immune system modifications in early pregnancy

November 14, 2018
The first Human Cell Atlas study of early pregnancy in humans has shown how the function of the maternal immune system is affected by cells from the developing placenta. Researchers from the Wellcome Sanger Institute, Newcastle ...

Soy formula feeding during infancy associated with severe menstrual pain in adulthood

November 9, 2018
New research suggests that infant girls fed soy formula are more likely to develop severe menstrual pain as young adults. The finding adds to the growing body of literature that suggests exposure to soy formula during early ...

A major role for a small organ in the immune response during pregnancy

November 9, 2018
The immune system of a pregnant woman is altered during pregnancy, but not in the way previously believed, according to results from a study at Linköping University, Sweden. This study, published in the Journal of Allergy ...

Mailed HPV tests can help find women at-risk for cervical cancer, study finds

November 7, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that mailing self-collection kits to test for high-risk human papillomavirus infection has the potential to boost cervical cancer ...

Women who give birth to boys much more likely to have postnatal depression

November 6, 2018
A University of Kent study into postnatal depression (PND) found the odds of developing this condition increased by 79% when mothers had baby boys compared to baby girls.

New study takes first step toward treating endometriosis

November 1, 2018
Researchers at Northwestern Medicine have taken the first step in bioengineering the human uterus to treat endometriosis, uterine-factor infertility and endometrial cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.